Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches

被引：52
作者：
Kim, Kook Hwan [1 ]
Lee, Myung-Shik [1 ,2 ]
机构：
[1] Yonsei Univ, Severance Biomed Res Inst, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源：
FRONTIERS IN ENDOCRINOLOGY | 2018年 / 9卷
基金：
新加坡国家研究基金会;
关键词：
NAFLD; NASH; steatosis; inflammation; fibrosis; multiple-parallel hit; FATTY LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; GROWTH-FACTOR; 21; GLUCAGON-LIKE PEPTIDE-1; INFLAMMATORY EXTRACELLULAR VESICLES; DIFFERENTIATION FACTOR 15; HEPATIC STELLATE CELLS; ADIPOSE-TISSUE; INSULIN-RESISTANCE; GENETIC-VARIATION;
D O I：
10.3389/fendo.2018.00485
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is an emerging global health problem and a potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney disease. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, is a predisposing factor for development of cirrhosis and hepatocellular carcinoma. The increasing prevalence of NASH emphasizes the need for novel therapeutic approaches. Although therapeutic drugs against NASH are not yet available, fundamental insights into the pathogenesis of NASH have been made during the past few decades. Multiple therapeutic strategies have been developed and are currently being explored in clinical trials or preclinical testing. The pathogenesis of NASH involves multiple intracellular/extracellular events in various cell types in the liver or crosstalk events between the liver and other organs. Here, we review current findings and knowledge regarding the pathogenesis of NASH, focusing on the most recent advances. We also highlight hormone-based therapeutic approaches for treatment of NASH.
引用
收藏
页数：14
相关论文
共 146 条
  • [1] Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., Et al., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, pp. 11-20, (2018)
  • [2] Michelotti G.A., Machado M.V., Diehl A.M., NAFLD, NASH and liver cancer, Nat Rev Gastroenterol Hepatol, 10, pp. 656-665, (2013)
  • [3] Anstee Q.M., Targher G., Day C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, pp. 330-344, (2013)
  • [4] Magee N., Zou A., Zhang Y., Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells, BioMed Res Int, 2016, (2016)
  • [5] Vonghia L., Francque S., Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: pathology and beyond, World J Hepatol, 7, pp. 1905-1912, (2015)
  • [6] Marra F., Svegliati-Baroni G., Lipotoxicity and the gut-liver axis in NASH pathogenesis, J Hepatol, 68, pp. 280-295, (2018)
  • [7] Tilg H., Moschen A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology, 52, pp. 1836-1846, (2010)
  • [8] Brunt E.M., Wong V.W., Nobili V., Day C.P., Sookoian S., Maher J.J., Et al., Nonalcoholic fatty liver disease, Nat Rev Dis Primers, 1, (2015)
  • [9] Luyckx F.H., Lefebvre P.J., Scheen A.J., Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss, Diabetes Metab, 26, pp. 98-106, (2000)
  • [10] Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., Et al., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, pp. 1844-1850, (2001)
12345678910